Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Bronchiolitis
Interventions
DRUG

Peginterferon α-2b injection

Peginterferon α-2b injection, 90 mcg, on the basis of conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, nebulized inhalation using air compression or oxygen-driven methods is administered on days 1, 3, and 5, once a day.

DRUG

Recombinant Human Interferon α2b

Recombinant Human Interferon alpha 2b, at a dose of 100,000 IU/kg, based on the conventional treatments such as asthma control, oxygen inhalation, and fluid replacement, will be administered via nebulized inhalation using air compression or oxygen-driven methods from day 1 to day 5, twice daily.

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Wuhan Women and Children's Health Care Center, Wuhan

RECRUITING

Children's Hospital of Soochow University, Suzhou

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Children's Hospital of Soochow University

OTHER